Intestinal Behçet’s disease appearing during treatment with adalimumab in a patient with ankylosing spondylitis

Sook Hee Chung, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Tae Il Kim, Won Ho Kim

Sook Hee Chung, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, South Korea

Author contributions: Chung SH wrote the manuscript; Park SJ designed the research and performed peer review; Cheon JH analyzed the clinical data and consulted about pathologic data and medical agents; Hong SP, Kim TI and Kim WH reviewed the manuscript.

Correspondence to: Soo Jung Park, MD, PhD, Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonseiro, Seodaemun-gu, Seoul 120-752, South Korea. sjpark@yuhs.ac

Telephone: +82-2-22281963 Fax: +82-2-3936884

Received: April 15, 2013 Revised: June 5, 2013 Accepted: July 18, 2013 Published online: August 28, 2013

Abstract

Behçet’s disease (BD) is a chronic inflammatory disease affecting multiple organ systems, such as the skin, joints, blood vessels, central nervous system, and gastrointestinal tract. Intestinal BD is characterized by intestinal ulcerations and gastrointestinal symptoms. The medical treatment of intestinal BD includes corticosteroids and immunosuppressants. There have been several reports of tumor necrosis factor-α (TNF-α) blockers being successful in treatment of refractory intestinal BD. Here, we report on a patient who was diagnosed with intestinal BD despite being treated with the fully humanized TNF-α blocker (adalimumab) for underlying ankylosing spondylitis. This patient achieved clinical remission and complete mucosal healing through the addition of a steroid and azathioprine to the adalimumab regimen.

© 2013 Baishideng. All rights reserved.

Key words: Intestinal Behçet’s disease; Tumor necrosis factor-α; Adalimumab

Case report

Here, we report on a patient who was diagnosed with intestinal Behçet’s disease despite treatment with the fully humanized tumor necrosis factor-α blocker (adalimumab) for underlying ankylosing spondylitis. This patient achieved clinical remission and complete mucosal healing through the addition of a steroid and azathioprine to the adalimumab regimen.


Introduction

Behçet’s disease (BD) involves multiple organ systems, such as the skin, joints, blood vessels, central nervous system, and gastrointestinal (GI) tract[1]. Intestinal BD is characterized by intestinal ulcerations and gastrointestinal symptoms[2]. The incidence of BD involving the GI tract varies by country, ranging from 3% to 60% of cases of BD[3]. GI bleeding and perforation can be associated with intestinal BD, with resultant comorbidities[4]. The medical treatment for intestinal BD includes corticosteroids and immunosuppressants. Unfortunately, surgical treatment, such as ileocolic resection, is sometimes necessary for intestinal BD with perforation, intractable pain, and hemorrhage which are refractory to conventional therapy[5]. There have been several reports of tumor necrosis factor-α (TNF-α) blockers being successful in refractory intestinal BD. Most of these were reported on the efficacy of infliximab[6-9] and a few reported on the efficacy of adalimumab[10,11]. Here, we report on a patient who was diagnosed with intestinal BD despite being treated with the fully humanized TNF-α blocker (adalimumab) for
underlying ankylosing spondylitis. This patient achieved and maintained clinical remission and complete mucosal healing through the addition of a steroid and azathioprine to the adalimumab regimen for 43 mo.

**CASE REPORT**

A 29-year-old male patient was hospitalized due to severe right lower quadrant abdominal pain for the preceding 15 d. He had experienced recurrent oral ulcerations and arthralgia for 15 years and had had an erythematous papule on his back for the past 2 years. He had undergone appendectomy for appendicitis 17 years ago. He was diagnosed with ankylosing spondylitis 2 years ago because of lower back and shoulder pain. He had taken salazopyrine 1000 mg for 2 mo and had been injected with infliximab for his ankylosing spondylitis for 9 mo (5 mg/kg intravenously at 0, 2 and 6 wk; 5 mg/kg intravenously every 8 wk). The oral ulcerations, arthralgias, and erythematous papule on his back had improved, but his back pain had not been improved at that time. Therefore, the infliximab had been switched to adalimumab (40 mg subcutaneously every 2 wk) since 10 mo ago. On physical examination at admission, he appeared acutely ill, and had a blood pressure of 120/70 mmHg, a pulse of 84 beats/min, a respiratory rate of 24 breaths/min, and a temperature of 36.5°C. The abdomen was flat with direct tenderness in the right lower quadrant. Bowel sounds were normal. The results of laboratory tests showed a white blood cell count (WBC) of 20930/mm³; hemoglobin, 13.9 g/dL; hematocrit, 41.7%; platelet count, 282000/mm³; total protein, 7.2 g/dL; erythrocyte sedimentation rate increased to 33 mm/h; and C-reactive protein increased to 111 mg/L. A colonoscopy performed on admission showed a well-demarcated, large, deep ulcer with an exudate, mucosal edema, and erythema at the terminal ileum (Figure 1A-C). Colonic biopsies at the terminal ileum showed an ulcer with a necroinflammatory exudate. On computed tomography, bowel wall thickening and prominent enhancement with surrounding fat infiltration were noted at the terminal ileum and cecum, suggesting active inflammation (Figure 2). Finally he was diagnosed as intestinal BD according to the clinical symptoms and examination. The disease activity index for intestinal Behçet’s disease (DAIBD) was 90, reflecting severe disease
activity. Subsequently, the patient was treated with conventional medical therapy, including azathioprine 150 mg and 5-aminosalicylate (5-ASA, Pentasa) 3000 mg/d. His abdominal pain seemed to decrease after 10 d. However, the patient’s severe right lower quadrant abdominal pain recurred after one month. The DAIBD score at the time of recurrent abdominal pain was 80, again reflecting severe disease activity. In the early stages of treatment, clinical remission could not be obtained through combination therapy with azathioprine and 5-ASA. Thus, at the time of abdominal pain recurrence, intravenous hydrocortisone (300 mg/d) was administrated. Then the abdominal pain was improved 2 d after steroid injection. Intravenous hydrocortisone was slowly tapered to oral prednisolone for 2 mo. Finally, DAIBD score was 10. A follow-up colonoscopy after 36 mo demonstrated that the ulcer at the terminal ileum was replaced by normal mucosa (Figure 1D-F) with complete mucosal healing. Combination therapy with azathioprine, 5-ASA and adalimumab was continued for 43 mo with clinical and endoscopic remission.

**DISCUSSION**

We reported on a 29-year-old man with BD and ankylosing spondylitis who developed intestinal BD despite continuous use of adalimumab. We treated this patient with intravenous steroids to induce clinical remission and with azathioprine and 5-ASA for maintenance of remission. This case is unique in two ways. First, the terminal ileal ulcer characteristic of intestinal BD appeared while the patient was receiving adalimumab for ankylosing spondylitis. Second, mucosal healing was achieved and maintained through combination therapy with azathioprine and 5-ASA after induction of remission with intravenous steroids.

Conventional therapies such as mesalamine, corticosteroids, immunosuppressive agents, thalidomide, bowel rest, and total parenteral nutrition have been used in the treatment of intestinal BD. However, in patients with intestinal BD unresponsive to conventional therapies, TNF-α blockers have been shown to improve symptoms. Both infliximab and adalimumab can be used for treatment of intestinal BD because they are similar active biologics, monoclonal antibodies to TNF-α. There has been no data available regarding the comparative efficacy of infliximab and adalimumab in intestinal BD. In Table 1 there have been many publications reporting on the effectiveness of infiximab. However, there have been only a few reports of the efficacy of adalimumab.

Table 1  Clinical characteristics of patients with intestinal Behçet’s disease receiving infliximab or adalimumab

<table>
<thead>
<tr>
<th>Case</th>
<th>Age (yr)/gender</th>
<th>Duration of disease (yr)</th>
<th>Anti TNF-α Ab for induction</th>
<th>Previous therapies</th>
<th>Maintenance therapy</th>
<th>Outcomes</th>
<th>Follow-up duration after achieving remission</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>32/F</td>
<td>5</td>
<td>IFX</td>
<td>Steroids 6-MP</td>
<td>IFX 6-MP</td>
<td>Remission</td>
<td>9 mo</td>
<td>[14]</td>
</tr>
<tr>
<td>2</td>
<td>37/F</td>
<td>2</td>
<td>IFX</td>
<td>Mesalamine Steroids 6-MP</td>
<td>IFX 6-MP</td>
<td>Remission</td>
<td>16 mo</td>
<td>[14]</td>
</tr>
<tr>
<td>3</td>
<td>51/M</td>
<td>4</td>
<td>IFX</td>
<td>Steroids Methotrexate Steroids Colchicines Cyclosporine A</td>
<td>IFX</td>
<td>Remission</td>
<td>3 yr</td>
<td>[14]</td>
</tr>
<tr>
<td>4</td>
<td>38/M</td>
<td>5</td>
<td>IFX</td>
<td>Steroids Azathioprine</td>
<td>AZA Surgery</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>43/F</td>
<td>6</td>
<td>IFX</td>
<td>Steroids Azathioprine</td>
<td>Steroids 6-MP</td>
<td>Remission</td>
<td>2 yr</td>
<td>[14]</td>
</tr>
<tr>
<td>6</td>
<td>38/M</td>
<td>3</td>
<td>IFX</td>
<td>Steroids Azathioprine</td>
<td>Steroids 6-MP Methotrexate</td>
<td>Remission</td>
<td>17 mo</td>
<td>[5]</td>
</tr>
<tr>
<td>7</td>
<td>35/F</td>
<td>Over 20</td>
<td>IFX</td>
<td>Steroids Azathioprine</td>
<td>Steroids 6-MP</td>
<td>Remission</td>
<td>10 mo</td>
<td>[5]</td>
</tr>
<tr>
<td>8</td>
<td>27/F</td>
<td>2</td>
<td>IFX</td>
<td>Thalidomide Steroids Colchicines Cyclosporine A</td>
<td>Steroids Thalidomide Thalidomide</td>
<td>Remission</td>
<td>10 mo</td>
<td>[5]</td>
</tr>
<tr>
<td>9</td>
<td>30/F</td>
<td>3</td>
<td>IFX</td>
<td>Azathioprine Sulfasalazine Steroids Azathioprine</td>
<td>Steroids 6-MP</td>
<td>Remission</td>
<td>12 mo</td>
<td>[4]</td>
</tr>
<tr>
<td>10</td>
<td>42/M</td>
<td>11</td>
<td>IFX</td>
<td>Colchicines Sulfasalazine Steroids Azathioprine</td>
<td>Steroids 6-MP</td>
<td>Remission</td>
<td>12 mo</td>
<td>[4]</td>
</tr>
<tr>
<td>11</td>
<td>47/M</td>
<td>20</td>
<td>IFX</td>
<td>Steroids Azathioprine</td>
<td>Steroids 6-MP</td>
<td>Remission</td>
<td>12 mo</td>
<td>[4]</td>
</tr>
<tr>
<td>12</td>
<td>30/F</td>
<td>-</td>
<td>IFX</td>
<td>Steroids Azathioprine</td>
<td>Steroids 6-MP</td>
<td>Remission</td>
<td>22 mo</td>
<td>[10]</td>
</tr>
<tr>
<td>13</td>
<td>45/F</td>
<td>9</td>
<td>IFX</td>
<td>Mesalamine Steroids</td>
<td>IFX Switch to adalimumab</td>
<td>Remission</td>
<td>25 wk</td>
<td>[6]</td>
</tr>
</tbody>
</table>

1Duration between remission stage and the first relapse stage after infusion of anti tumor necrosis factor-α antibody (anti TNF-α Ab). F: Female; M: Male; IFX: Infliximab; 6-MP: 6-mercaptopurine.

Chung SH et al. Intestinal Behçet’s disease appearing during adalimumab treatment
in treating intestinal BD\textsuperscript{10,11}. Infliximab with combination therapies, such as 5-ASA and immunosuppressants, in patients with intestinal BD is effective for the induction and maintenance of remission\textsuperscript{[4,9,11,14]}. In the case of adalimumab, adalimumab was reported to be effective in inducing complete remission as monotherapy\textsuperscript{[10]}. We suggest three reasons why this patient may have developed an ulcer of the terminal ileum during the use of adalimumab, but not during the use of infliximab. First, the two medicines have different routes of injection, with adalimumab injected subcutaneously (SQ) and infliximab injected intravenously. When infliximab is injected intravenously, it enters the venous circulation directly with 100% bioavailability and no absorption phase, thereby reaching a more rapid therapeutic range than achieved with subcutaneous injection. Conversely, the bioavailability of an adalimumab 40 mg SQ dose has been estimated as 64%\textsuperscript{[10]}. Second, there might be a difference in the effective dose between adalimumab and infliximab. Adalimumab is used to be injected as fixed dose irrespective of body weight (40 mg subcutaneously every 2 wk) but infliximab is used to be injected according to the body weight (5 mg/kg at 0, 2 and 6 wk; 5 mg/kg every 8 wk). Compared to the infliximab, adalimumab in fixed dose was supposed to be less effective in this patient with 22.8 kg/m\textsuperscript{2} body mass index because of shortage of dose. Third, intravenous injection might be more potent than subcutaneous injection because BD is characterized by systemic vasculitis\textsuperscript{[10]}. Infliximab and adalimumab are different medicines having unique pharmacokinetics. There was no head to head study for comparing effectiveness of infliximab and adalimumab. Further studies are warranted to compare the efficacy of adalimumab and infliximab in patients with intestinal BD.

In conclusion, this is the first case report of intestinal BD appearing despite the use of adalimumab. Furthermore, the subject in this case improved with the combination of intravenous steroids, azathioprine, and 5-ASA might be important in treating patients with intestinal BD.

REFERENCES


P- Reviewers Cuzzocrea S, Lukashevich IS E- Editor Zhai HH L- Editor A E- Editor Zhang DN